A new drug called denosumab may soon give Zometa (zoledronic acid) competition as the standard of care in treating bone metastases in patients with advanced breast cancer. Patients taking denosumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback